13F filer · CIK 1479355
VHCP Management, LLC
NEW YORK, NY · filing since Q2 2013 · last filing Feb 13, 2017
Reported value
$101.7M
+$5.2M vs prior
Positions
24
New / sold out
3 / 2
Added / reduced
2 / 2
Turnover
4.6%
buys $4.6M · sells $11.6M
Top-10 weight
84.5%
Biggest buys vs Q2 2016
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | CoLucid Pharmaceuticals | +68,190 | – | +$2.6M |
| New | Achillion Pharmaceuticals Inc | +180,000 | – | +$1.5M |
| New | Audentes Therapeutics | +15,000 | – | +$267.0K |
| Added | Ocera Therapeutics | +60,000 | +7.5% | +$158.4K |
| Added | Alcobra Ltd | +35,597 | +5.7% | +$88.0K |
Biggest sells vs Q2 2016
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Reduced | Coherus Biosciences Inc | -305,505 | -50.0% | $-8.2M |
| Sold out | Cynapsus Therapeutics Inc | -108,575 | -100.0% | $-1.8M |
| Sold out | Global Blood Therapeutics | -72,990 | -100.0% | $-1.2M |
| Reduced | REGENXBIO Inc | -28,411 | -54.1% | $-397.5K |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q3 2016
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | DBV TechnologiesCOM | 456,893 | $32.5M | 31.95% |
| 2 | Heron Therapeutics IncCOM | 1,095,734 | $18.9M | 18.57% |
| 3 | Coherus Biosciences IncCOM | 305,505 | $8.2M | 8.05% |
| 4 | Flamel Technologies S.A.COM | 500,000 | $6.2M | 6.10% |
| 5 | Adverum BiotechnologiesCOM | 1,102,735 | $4.5M | 4.46% |
| 6 | BioCryst Pharmaceuticals IncCOM | 1,005,104 | $4.4M | 4.36% |
| 7 | Lipocine IncCOM | 849,921 | $3.8M | 3.73% |
| 8 | CoLucid PharmaceuticalsCOM | 68,190 | $2.6M | 2.56% |
| 9 | Axovant Sciences LtdCOM | 184,110 | $2.6M | 2.54% |
| 10 | Ocera TherapeuticsCOM | 856,550 | $2.3M | 2.22% |
14 more rows. Subscribe for $29/month to see every row, download the data and use the API.